Literature DB >> 29106487

Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl.

Richard A C Hughes1, David R Cornblath2, Hugh J Willison3.   

Abstract

Keywords:  Guillain-Barré syndrome; Zika virus; history; pathology; treatment

Mesh：

Year:  2016        PMID： 29106487     DOI： 10.1093/brain/aww247

Source DB:  PubMed          Journal:  Brain        ISSN： 0006-8950            Impact factor:   13.501


× No keyword cloud information.
  5 in total

1.  An unusual occurrence of opsoclonus and liver enzymes elevation in a patient with acute motor and sensory axonal neuropathy subtype of Guillain-Barré syndrome.

Authors:  Hasan Alzuhaily; Eman Khashaneh; Sanaa Albkhetan; Fatima Abbas
Journal:  BMC Neurol       Date:  2022-03-18       Impact factor: 2.474

Review 2.  Axonal variants of Guillain-Barré syndrome: an update.

Authors:  Pei Shang; Mingqin Zhu; Ying Wang; Xiangyu Zheng; Xiujuan Wu; Jie Zhu; Jiachun Feng; Hong-Liang Zhang
Journal:  J Neurol       Date:  2020-03-05       Impact factor: 4.849

3.  Population Pharmacokinetic Modelling of Intravenous Immunoglobulin Treatment in Patients with Guillain-Barré Syndrome.

Authors:  Willem Jan R Fokkink; Sander J van Tilburg; Brenda C M de Winter; Sebastiaan D T Sassen; Pieter A van Doorn; Birgit C P Koch; Bart C Jacobs
Journal:  Clin Pharmacokinet       Date:  2022-07-04       Impact factor: 5.577

Review 4.  Facing acute neuromuscular diseases during COVID-19 pandemic: focus on Guillain-Barré syndrome.

Authors:  Giuliana Galassi; Alessandro Marchioni
Journal:  Acta Neurol Belg       Date:  2020-07-21       Impact factor: 2.396

5.  Increased serum neurofilament light chain concentration indicates poor outcome in Guillain-Barré syndrome.

Authors:  Patrick Altmann; Desiree De Simoni; Alexandra Kaider; Birgit Ludwig; Jakob Rath; Fritz Leutmezer; Fritz Zimprich; Romana Hoeftberger; Michael P Lunn; Amanda Heslegrave; Thomas Berger; Henrik Zetterberg; Paulus Stefan Rommer
Journal:  J Neuroinflammation       Date:  2020-03-17       Impact factor: 8.322
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.